Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and…
| Price | $18.44 |
|---|---|
| Market cap | $372.84M |
| Sector | Technology |
| Industry | Software - Application |
| Exchange | NASDAQ |
| 52-week range | 11.09-21.01 |
| Beta | 1.33 |
Explore SLP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.